Extracellular Vesicles and Their Use as Vehicles of Immunogens.
CD8+ T cell immunity
EV biogenesis
EV composition
EV function
Enveloped viral vectors
Exosomes
Extracellular vesicles
Vaccines
Virus-like particles
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2022
2022
Historique:
entrez:
25
4
2022
pubmed:
26
4
2022
medline:
28
4
2022
Statut:
ppublish
Résumé
Healthy cells constitutively release lipid bilayered vesicles of different sizes and recognizing different biogenesis, collectively referred to as extracellular vesicles (EVs). EVs can be distinguished in exosomes and microvesicles. Biological and biomedical research on EVs is an emerging field that is rapidly growing. Many EV features including biogenesis, cell uptake, and functions still require unambiguous elucidation. Nevertheless, it has been well established that EVs are involved in communication among cells, tissues, and organs under both healthy and disease conditions by virtue of their ability to deliver macromolecules to target cells. Here, we summarize most recent findings regarding biogenesis, structure, and functions of both exosomes and microvesicles. In addition, the use of EVs as delivery tools to induce CD8
Identifiants
pubmed: 35467287
doi: 10.1007/978-1-0716-2341-1_13
doi:
Substances chimiques
Macromolecular Substances
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
177-198Informations de copyright
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
Références
György B, Szabó TG, Pásztói M et al (2011) Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci 68(16):2667–2688. https://doi.org/10.1007/s00018-011-0689-3
doi: 10.1007/s00018-011-0689-3
pubmed: 21560073
pmcid: 3142546
Mathivanan S, Fahner CJ, Reid GE, Simpson RJ (2012) ExoCarta 2012: database of exosomal proteins, RNA and lipids. Nucleic Acids Res 40:D1241–D1244. https://doi.org/10.1093/nar/gkr828
doi: 10.1093/nar/gkr828
pubmed: 21989406
Van Niel G, D’Angelo G, Raposo G (2018) Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol 19(4):213–228. https://doi.org/10.1038/nrm.2017.125
doi: 10.1038/nrm.2017.125
pubmed: 29339798
Arenaccio C, Federico M (2017) The multifaceted functions of exosomes in health and disease: an overview. Adv Exp Med Biol 998:3–19. https://doi.org/10.1007/978-981-10-4397-0_1
doi: 10.1007/978-981-10-4397-0_1
pubmed: 28936729
Théry C, Amigorena S, Raposo G, Clayton A (2006) Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol 30:3.22.1–3.22.29. https://doi.org/10.1002/0471143030.cb0322s30
doi: 10.1002/0471143030.cb0322s30
Johnstone RM, Adam M, Hammond JR et al (1987) Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem 262(19):9412–9420
doi: 10.1016/S0021-9258(18)48095-7
Colombo M, Raposo G, Thery C (2014) Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol 30:255–289. https://doi.org/10.1146/annurev-cellbio-101512-122326
doi: 10.1146/annurev-cellbio-101512-122326
pubmed: 25288114
Stoorvogel W, Kleijmeer MJ, Geuze HJ et al (2002) The biogenesis and functions of exosomes. Traffic 3:321–330. https://doi.org/10.1034/j.1600-0854.2002.30502.x
doi: 10.1034/j.1600-0854.2002.30502.x
pubmed: 11967126
Schorey JS, Bhatnagar S (2008) Exosome function: from tumor immunology to pathogen biology. Traffic 9:871–881. https://doi.org/10.1111/j.1600-0854.2008.00734.x
doi: 10.1111/j.1600-0854.2008.00734.x
pubmed: 18331451
pmcid: 3636814
Williams RL, Urbe S (2007) The emerging shape of the ESCRT machinery. Nat Rev Mol Cell Biol 8:355–368. https://doi.org/10.1038/nrm2162
doi: 10.1038/nrm2162
pubmed: 17450176
Rusten TE, Vaccari T, Stenmark H (2012) Shaping development with ESCRTs. Nat Cell Biol 14:38–45. https://doi.org/10.1038/ncb2381
doi: 10.1038/ncb2381
Stuffers S, SemWegner C, Stenmark H et al (2009) Multivesicular endosome biogenesis in the absence of ESCRTs. Traffic 10:925–937. https://doi.org/10.1111/j.1600-0854.2009.00920.x
doi: 10.1111/j.1600-0854.2009.00920.x
pubmed: 19490536
Trajkovic K, Hsu C, Chiantia S et al (2008) Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 319:1244–1247. https://doi.org/10.1126/science.115312
doi: 10.1126/science.115312
pubmed: 18309083
Deolindo P, Evans-Osses I, Ramirez MI (2013) Microvesicles and exosomes as vehicles between protozoan and host cell communication. Biochem Soc Trans 41(1):252–257. https://doi.org/10.1042/BST20120217
doi: 10.1042/BST20120217
pubmed: 23356292
Cocucci E, Racchetti G, Meldolesi J (2009) Shedding microvesicles: artefacts no more. Trends Cell Biol 19(2):43–51. https://doi.org/10.1016/j.tcb.2008.11.003
doi: 10.1016/j.tcb.2008.11.003
pubmed: 19144520
Latifkar A, Hur YH, Sanchez JC et al (2019) New insights into extracellular vesicle biogenesis and function. J Cell Sci 132(13):jcs222406. https://doi.org/10.1242/jcs.222406
doi: 10.1242/jcs.222406
pubmed: 31263077
pmcid: 6633391
Shen B, Wu N, Yang JM, Gould SJ (2011) Protein targeting to exosomes/microvesicles by plasma membrane anchors. J Biol Chem 286(16):14383–14395. https://doi.org/10.1074/jbc.M110.208660
doi: 10.1074/jbc.M110.208660
pubmed: 21300796
pmcid: 3077638
Villarroya-Beltri C, Gutiérrez-Vázquez C, Sánchez-Cabo F et al (2013) Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs. Nat Commun 4:2980. https://doi.org/10.1038/ncomms3980
doi: 10.1038/ncomms3980
pubmed: 24356509
Santangelo L, Giurato G, Cicchini C et al (2016) The RNA-binding protein SYNCRIP is a component of the hepatocyte exosomal machinery controlling microRNA sorting. Cell Rep 17:799–808. https://doi.org/10.1016/j.celrep.2016.09.031
doi: 10.1016/j.celrep.2016.09.031
pubmed: 27732855
Théry C, Ostrowski M, Segura E (2009) Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 9:581–593. https://doi.org/10.1038/nri2567
doi: 10.1038/nri2567
pubmed: 19498381
Lakhal S, Wood MJ (2011) Exosome nanotechnology: an emerging paradigm shift in drug delivery. Exploitation of exosome nanovesicles for systemic in vivo delivery of RNAi heralds new horizons for drug delivery across biological barriers. Bioessays 33:737–741. https://doi.org/10.1002/bies.201100076
doi: 10.1002/bies.201100076
pubmed: 21932222
Valadi H, Ekström K, Bossios A et al (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9(6):654–659. https://doi.org/10.1038/ncb1596
doi: 10.1038/ncb1596
pubmed: 17486113
Al-Nedawi K, Meehan B, Micallef J et al (2008) Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 10(5):619–624. https://doi.org/10.1038/ncb1725
doi: 10.1038/ncb1725
pubmed: 18425114
Montecalvo A, Larregina AT, Shufesky WJ et al (2012) Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood 119:756–766. https://doi.org/10.1182/blood-2011-02-338004
doi: 10.1182/blood-2011-02-338004
pubmed: 22031862
pmcid: 3265200
Berckmans RJ, Sturk A, van Tienen LM et al (2011) Cell-derived vesicles exposing coagulant tissue factor in saliva. Blood 117(11):3172–3180. https://doi.org/10.1182/blood-2010-06-290460
doi: 10.1182/blood-2010-06-290460
pubmed: 21248061
Biro E, Sturk-Maquelin KN, Vogel GM et al (2003) Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner. J Thromb Haemost 1(12):2561–2568. https://doi.org/10.1046/j.1538-7836.2003.00456.x
doi: 10.1046/j.1538-7836.2003.00456.x
pubmed: 14738565
Taylor DD, Akyol S, Gercel-Taylor C (2006) Pregnancy-associated exosomes and their modulation of T cell signaling. J Immunol 176(3):1534–1542. https://doi.org/10.4049/jimmunol.176.3.1534.2
doi: 10.4049/jimmunol.176.3.1534.2
pubmed: 16424182
Cui G, Guo H, Li H et al (2019) RVG-modified exosomes derived from mesenchymal stem cells rescue memory deficits by regulating inflammatory responses in a mouse model of Alzheimer’s disease. Immun Ageing 16:10. https://doi.org/10.1186/s12979-019-0150-2
doi: 10.1186/s12979-019-0150-2
pubmed: 31114624
pmcid: 6515654
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. https://doi.org/10.1016/j.cell.2011.02.013
doi: 10.1016/j.cell.2011.02.013
pubmed: 21376230
Buzas EI, György B, Nagy G et al (2014) Emerging role of extracellular vesicles in inflammatory diseases. Nat Rev Rheumatol 10(6):356–364. https://doi.org/10.1038/nrrheum.2014.19
doi: 10.1038/nrrheum.2014.19
pubmed: 24535546
Silverman JM, Reiner NE (2011) Exosomes and other microvesicles in infection biology: organelles with unanticipated phenotypes. Cell Microbiol 13:1–9. https://doi.org/10.1111/j.1462-5822.2010.01537.x
doi: 10.1111/j.1462-5822.2010.01537.x
pubmed: 21040357
Schwab A, Meyering SS, Lepene B et al (2015) Extracellular vesicles from infected cells: potential for direct pathogenesis. Front Microbiol 6:1132. https://doi.org/10.3389/fmicb.2015.01132
doi: 10.3389/fmicb.2015.01132
pubmed: 26539170
pmcid: 4611157
Yim KHW, Al-Hrout AN, Borgoni S, Chahwan R (2020) Extracellular vesicles orchestrate immune and tumor interaction networks. Cancers (Basel) 12(12):3696. https://doi.org/10.3390/cancers12123696
doi: 10.3390/cancers12123696
Peinado H, Alečković M, Lavotshkin S et al (2012) Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 18:883–891. https://doi.org/10.1038/nm.2753
doi: 10.1038/nm.2753
pubmed: 22635005
pmcid: 3645291
Abusamra AJ, Zhong Z, Zheng X et al (2005) Tumor exosomes expressing Fas ligand mediate CD8+T-cell apoptosis. Blood Cells Mol Dis 35(2):169–173. https://doi.org/10.1016/j.bcmd.2005.07.001
doi: 10.1016/j.bcmd.2005.07.001
pubmed: 16081306
Raposo G, Nijman HW, Stoorvogel W et al (1996) B lymphocytes secrete antigen-presenting vesicles. J Exp Med 183:1161–1172. https://doi.org/10.1084/jem.183.3.1161
doi: 10.1084/jem.183.3.1161
pubmed: 8642258
McNamara RP, Costantini LM, Myers TA et al (2018) Nef secretion into extracellular vesicles or exosomes is conserved across human and simian immunodeficiency viruses. mBio 9(1):e02344–e02317. https://doi.org/10.1128/mBio.02344-17
doi: 10.1128/mBio.02344-17
pubmed: 29437924
pmcid: 5801467
Gooz M (2010) ADAM-17: the enzyme that does it all. Crit Rev Biochem Mol Biol 45(2):146–169. https://doi.org/10.3109/10409231003628015
doi: 10.3109/10409231003628015
pubmed: 20184396
pmcid: 2841225
Arenaccio C, Chiozzini C, Columba-Cabezas S et al (2014) Exosomes from human immunodeficiency virus type 1 (HIV-1)-infected cells license quiescent CD4+ T lymphocytes to replicate HIV-1 through a Nef- and ADAM17-dependent mechanism. J Virol 88(19):11529–11539. https://doi.org/10.1128/JVI.01712-14
doi: 10.1128/JVI.01712-14
pubmed: 25056899
pmcid: 4178784
Lee JH, Ostalecki C, Zhao Z et al (2018) HIV activates the tyrosine kinase Hck to secrete ADAM protease-containing extracellular vesicles. EBioMedicine 28(2018):151–161. https://doi.org/10.1016/j.ebiom.2018.01.004
doi: 10.1016/j.ebiom.2018.01.004
pubmed: 29331674
pmcid: 5836510
Arenaccio C, Anticoli S, Manfredi F et al (2015) Latent HIV-1 is activated by exosomes from cells infected with either replication-competent or defective HIV-1. Retrovirology 12:87. https://doi.org/10.1186/s12977-015-0216-y
doi: 10.1186/s12977-015-0216-y
pubmed: 26502902
pmcid: 4623921
Hong X, Schouest B, Xu H et al (2017) Effects of exosome on the activation of CD4+ T cells in rhesus macaques: a potential application for HIV latency reactivation. Sci Rep 7(1):15611. https://doi.org/10.1038/s41598-017-15961-x
doi: 10.1038/s41598-017-15961-x
pubmed: 29142313
pmcid: 5688118
Lee JH, Schierer S, Blume K et al (2016) HIV-nef and ADAM17-containing plasma extracellular vesicles induce and correlate with immune pathogenesis in chronic HIV infection. EBioMedicine 6:103–113. https://doi.org/10.1016/j.ebiom.2016.03.004
doi: 10.1016/j.ebiom.2016.03.004
pubmed: 27211553
pmcid: 4856776
Jones RB, Walker BD (2016) HIV-specific CD8
doi: 10.1172/JCI80566
pubmed: 26731469
pmcid: 4731167
Channappanavar R, Zhao J, Perlman S (2014) T cell-mediated immune response to respiratory coronaviruses. Immunol Res 59(1–3):118–128. https://doi.org/10.1007/s12026-014-8534-z
doi: 10.1007/s12026-014-8534-z
pubmed: 24845462
pmcid: 4125530
Wilson JA, Hart MK (2001) Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein. J Virol 75(6):2660–2664. https://doi.org/10.1128/JVI.75.6.2660-2664.2001
doi: 10.1128/JVI.75.6.2660-2664.2001
pubmed: 11222689
pmcid: 115890
Netland J, Bevan MJ (2013) CD8 and CD4 T cells in west nile virus immunity and pathogenesis. Viruses 5(10):2573–2584. https://doi.org/10.3390/v5102573
doi: 10.3390/v5102573
pubmed: 24153060
pmcid: 3814605
Valkenburg SA, Josephs TM, Clemens EB et al (2016) Molecular basis for universal HLA-A*0201-restricted CD8+ T-cell immunity against influenza viruses. Proc Natl Acad Sci U S A 113(16):4440–4445. https://doi.org/10.1073/pnas.1603106113
doi: 10.1073/pnas.1603106113
pubmed: 27036003
pmcid: 4843436
Aragon TJ, Ulrich S, Fernyak S, Rutherford GW (2003) Risks of serious complications and death from smallpox vaccination: a systematic review of the United States experience, 1963–1968. BMC Public Health 3:26. https://doi.org/10.1186/1471-2458-3-26
doi: 10.1186/1471-2458-3-26
pubmed: 12911836
pmcid: 194634
Stickl H, Hochstein-Mintzel V (1971) Intracutaneous smallpox vaccination with a weak pathogenic vaccinia virus (“MVA virus”). Munch Med Wochenschr 27(35):1149–1153
Antoine G, Scheiflinger F, Dorner F, Falkner FG (1998) The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244(2):365–396. https://doi.org/10.1006/viro.1998.9123
doi: 10.1006/viro.1998.9123
pubmed: 9601507
Panicali D, Davis SW, Weinberg RL, Paoletti E (1983) Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proc Natl Acad Sci U S A 80(17):5364–5368. https://doi.org/10.1073/pnas.80.17.5364
doi: 10.1073/pnas.80.17.5364
pubmed: 6310573
pmcid: 384256
Moss B, Smith GL, Gerin JL, Purcell RH (1984) Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature 311:67–69. https://doi.org/10.1038/311067a0
doi: 10.1038/311067a0
pubmed: 6472464
Sutter G, Ramsey-Ewing A, Rosales R, Moss B (1994) Stable expression of the vaccinia virus K1L gene in rabbit cells complements the host range defect of a vaccinia virus mutant. J Virol 68:4109–4116. https://doi.org/10.1128/JVI.68.7.4109-4116.1994
doi: 10.1128/JVI.68.7.4109-4116.1994
pubmed: 8207789
pmcid: 236334
Wyatt LS, Carroll MW, Czerny CP et al (1998) Marker rescue of the host range restriction defects of modified vaccinia virus Ankara. Virology 251:334–342. https://doi.org/10.1006/viro.1998.9397
doi: 10.1006/viro.1998.9397
pubmed: 9837798
Volz A, Sutter G (2017) Modified vaccinia virus Ankara: history, value in basic research, and current perspectives for vaccine development. Adv Virus Res 97:187–243. https://doi.org/10.1016/bs.aivir.2016.07.001
doi: 10.1016/bs.aivir.2016.07.001
pubmed: 28057259
Di Pilato M, Sánchez-Sampedro L, Mejías-Pérez E et al (2015) Modification of promoter spacer length in vaccinia virus as a strategy to control the antigen expression. J Gen Virol 96(8):2360–2371. https://doi.org/10.1099/vir.0.000183
doi: 10.1099/vir.0.000183
pubmed: 25972354
Domi A, Moss B (2002) Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells. Proc Natl Acad Sci U S A 99(19):12415–12420. https://doi.org/10.1073/pnas.192420599
doi: 10.1073/pnas.192420599
pubmed: 12196634
pmcid: 129459
Yuan M, Zhang W, Wang J et al (2015) Efficiently editing the vaccinia virus genome by using the CRISPR-Cas9 system. J Virol 89(9):5176–5179. https://doi.org/10.1128/JVI.00339-15
doi: 10.1128/JVI.00339-15
pubmed: 25741005
pmcid: 4403460
Guerra S, González JM, Climent N et al (2010) Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS. J Virol 84(16):8141–8152. https://doi.org/10.1128/JVI.00749-10
doi: 10.1128/JVI.00749-10
pubmed: 20534857
pmcid: 2916545
Schneider J, Gilbert SC, Blanchard TJ et al (1998) Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 4(4):397–402. https://doi.org/10.1038/nm0498-397
doi: 10.1038/nm0498-397
pubmed: 9546783
Milligan ID, Gibani MM, Sewell R et al (2016) Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial. JAMA 315(15):1610–1623. https://doi.org/10.1001/jama.2016.4218
doi: 10.1001/jama.2016.4218
pubmed: 27092831
Tameris MD, Hatherill M, Landry BS et al (2013) Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381(9871):1021–1028. https://doi.org/10.1016/S0140-6736(13)60177-4
doi: 10.1016/S0140-6736(13)60177-4
pubmed: 23391465
pmcid: 5424647
Joachim A, Nilsson C, Aboud S et al (2015) Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults. PLoS One 10(4):e0118486. https://doi.org/10.1371/journal.pone.0118486
doi: 10.1371/journal.pone.0118486
pubmed: 25874723
pmcid: 4396991
Cavenaugh JS, Awi D, Mendy M, Hill AV et al (2011) Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection. PLoS One 6(2):e14626. https://doi.org/10.1371/journal.pone.0014626
doi: 10.1371/journal.pone.0014626
pubmed: 21347224
pmcid: 3039644
Rehm KE, Roper RL (2011) Deletion of the A35 gene from modified vaccinia virus Ankara increases immunogenicity and isotype switching. Vaccine 29:3276–3283. https://doi.org/10.1016/j.vaccine.2011.02.023
doi: 10.1016/j.vaccine.2011.02.023
pubmed: 21352940
pmcid: 3078999
Mandl SJ, Rountree RB, Dalpozzo K et al (2012) Immunotherapy with MVA-BN®HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells. Cancer Immunol Immunother 61(1):19–29. https://doi.org/10.1007/s00262-011-1077-4
doi: 10.1007/s00262-011-1077-4
pubmed: 21822917
Zuhair M, Smit GSA, Wallis G et al (2019) Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis. Rev Med Virol 29(3):e2034. https://doi.org/10.1002/rmv.2034
doi: 10.1002/rmv.2034
pubmed: 30706584
Dunn W, Chou C, Li H et al (2003) Functional profiling of a human cytomegalovirus genome. Proc Natl Acad Sci U S A 100(24):14223–14228. https://doi.org/10.1073/pnas.2334032100
doi: 10.1073/pnas.2334032100
pubmed: 14623981
pmcid: 283573
Schleiss MR, Permar SR, Plotkin SA et al (2017) Progress toward development of a vaccine against congenital cytomegalovirus infection. Clin Vaccine Immunol 24:e00268–e00217. https://doi.org/10.1128/CVI.00268-17
doi: 10.1128/CVI.00268-17
pubmed: 29046308
pmcid: 5717185
Klenerman P, Oxenius A (2016) T cell responses to cytomegalovirus. Nat Rev Immunol 16:367–377. https://doi.org/10.1038/nri.2016.38
doi: 10.1038/nri.2016.38
pubmed: 27108521
Liu J, Jaijyan DK, Tang Q, Zhu H (2019) Promising cytomegalovirus-based vaccine vector induces robust CD8
doi: 10.3390/ijms20184457
pubmed: 31510028
Hansen SG, Ford JC, Lewis MS et al (2011) Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473(7348):523–527. https://doi.org/10.1038/nature10003
doi: 10.1038/nature10003
pubmed: 21562493
pmcid: 3102768
Qiu Z, Huang H, Grenier JM et al (2015) Cytomegalovirus-based vaccine expressing a modified tumor antigen induces potent tumor-specific CD8(+) T-cell response and protects mice from melanoma. Cancer Immunol Res 5:536–546. https://doi.org/10.1158/2326-6066
doi: 10.1158/2326-6066
Früh K, Picker L (2017) CD8+ T cell programming by cytomegalovirus vectors: applications in prophylactic and therapeutic vaccination. Curr Opin Immunol 47:52–56. https://doi.org/10.1016/j.coi.2017.06.010
doi: 10.1016/j.coi.2017.06.010
pubmed: 28734175
pmcid: 5626601
Lundstrom K (2005) Biology and applications of alphaviruses in gene therapy. Gene Ther 12:S92–S97. https://doi.org/10.1038/sj.gt.3302620
doi: 10.1038/sj.gt.3302620
pubmed: 16231060
Lundstrom K (2019) RNA viruses as tools in gene therapy and vaccine development. Genes 10(3):189. https://doi.org/10.3390/genes10030189
doi: 10.3390/genes10030189
pmcid: 6471356
Öhlund P, García-Arriaza J, Zusinaite E et al (2018) DNA-launched RNA replicon vaccines induce potent anti-Ebolavirus immune responses that can be further improved by a recombinant MVA boost. Sci Rep 8(1):12459. https://doi.org/10.1038/s41598-018-31003-6
doi: 10.1038/s41598-018-31003-6
pubmed: 30127450
pmcid: 6102224
Flatz L, Hegazy AN, Bergthaler A et al (2010) Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8
doi: 10.1038/nm.2104
pubmed: 20139992
pmcid: 3247638
Dhanwani R, Ly H (2016) Arenaviral vaccine vectors to combat infectious diseases. Oncotarget 7(29):44875. https://doi.org/10.18632/oncotarget.10405
doi: 10.18632/oncotarget.10405
pubmed: 27391429
pmcid: 5216690
Dhanwani R, Zhou Y, Huang Q et al (2015) A novel live Pichinde virus-based vaccine vector induces enhanced humoral and cellular immunity after a booster dose. J Virol 90(5):2551–2560. https://doi.org/10.1128/JVI.02705-15
doi: 10.1128/JVI.02705-15
pubmed: 26676795
Ryu BY, Evans-Galea MV, Gray JT et al (2008) An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation. Blood 111:1866–1875. https://doi.org/10.1182/blood-2007-04-085506
doi: 10.1182/blood-2007-04-085506
pubmed: 17991809
pmcid: 2234041
Schambach A, Zychlinski D, Ehrnstroem B, Baum C (2013) Biosafety features of lentiviral vectors. Hum Gene Ther 24:132–142. https://doi.org/10.1089/hum.2012.229
doi: 10.1089/hum.2012.229
pubmed: 23311447
pmcid: 3581032
Shaw A, Cornetta K (2014) Design and potential of non-integrating lentiviral vectors. Biomedicine 2:14–35. https://doi.org/10.3390/biomedicines2010014
doi: 10.3390/biomedicines2010014
Gallinaro A, Borghi M, Bona R et al (2018) Integrase defective lentiviral vector as a vaccine platform for delivering influenza antigens. Front Immunol 9:171. https://doi.org/10.3389/fimmu.2018.00171
doi: 10.3389/fimmu.2018.00171
pubmed: 29459873
pmcid: 5807328
Grasso F, Negri DRM, Mochi S et al (2013) Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein. Int J Cancer 132:335–344. https://doi.org/10.1002/ijc.27676
doi: 10.1002/ijc.27676
pubmed: 22700466
Karwacz K, Mukherjee S, Apolonia L et al (2009) Nonintegrating lentivector vaccines stimulate prolonged T-cell and antibody responses and are effective in tumor therapy. J Virol 83(7):3094–3103. https://doi.org/10.1128/JVI.02519-08
doi: 10.1128/JVI.02519-08
pubmed: 19176629
pmcid: 2655594
Coutant F, Sanchez David RY, Felix T et al (2012) A nonintegrative lentiviral vector-based vaccine provides long-term sterile protection against malaria. PLoS One 7:e48644. https://doi.org/10.1371/journal.pone.0048644
doi: 10.1371/journal.pone.0048644
pubmed: 23133649
pmcid: 3487763
Negri D, Blasi M, LaBranche C et al (2016) Immunization with an SIV-based IDLV expressing HIV-1 Env 1086 clade C elicits durable humoral and cellular responses in rhesus macaques. Mol Ther 24(11):2021–2032. https://doi.org/10.1038/mt.2016.123
doi: 10.1038/mt.2016.123
pubmed: 27455880
pmcid: 5154473
Gallinaro A, Borghi M, Pirillo MF et al (2020) Development and preclinical evaluation of an integrase defective lentiviral vector vaccine expressing the HIVACAT T cell immunogen in mice. Mol Ther Methods Clin Dev 17:418–428. https://doi.org/10.1016/j.omtm.2020.01.013
doi: 10.1016/j.omtm.2020.01.013
pubmed: 32154327
pmcid: 7056611
Sistigu A, Bracci L, Valentini M et al (2011) Strong CD8+ T cell antigenicity and immunogenicity of large foreign proteins incorporated in HIV-1 VLPs able to induce a Nef-dependent activation/maturation of dendritic cells. Vaccine 29(18):3465–3475. https://doi.org/10.1016/j.vaccine.2011.02.059
doi: 10.1016/j.vaccine.2011.02.059
pubmed: 21382480
Kushnir N, Streatfield SJ, Yusibov V (2012) Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine 31(1):58–83. https://doi.org/10.1016/j.vaccine.2012.10.083
doi: 10.1016/j.vaccine.2012.10.083
pubmed: 23142589
pmcid: 7115575
Martins K, Carra JH, Cooper CL et al (2015) Cross-protection conferred by Filovirus virus-like particles containing trimeric hybrid glycoprotein. Viral Immunol 28(1):62–70. https://doi.org/10.1089/vim.2014.0071
doi: 10.1089/vim.2014.0071
pubmed: 25514232
Zitvogel L, Regnault A, Lozier A et al (1998) Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 4(5):594–600. https://doi.org/10.1089/vim.2014.0071
doi: 10.1089/vim.2014.0071
pubmed: 9585234
Wolfers J, Lozier A, Raposo G et al (2001) Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 7(3):297–303. https://doi.org/10.1038/85438
doi: 10.1038/85438
pubmed: 11231627
Syn NL, Wang L, Chow EK et al (2017) Exosomes in cancer nanomedicine and immunotherapy: prospects and challenges. Trends Biotechnol 35(7):665–676. https://doi.org/10.1016/j.tibtech.2017.03.004
doi: 10.1016/j.tibtech.2017.03.004
pubmed: 28365132
Tan A, De La Peña H, Seifalian AM (2010) The application of exosomes as a nanoscale cancer vaccine. Int J Nanomedicine 5:889–900. https://doi.org/10.2147/IJN.S13402
doi: 10.2147/IJN.S13402
pubmed: 21116329
pmcid: 2990382
Chaput N, Théry C (2011) Exosomes: immune properties and potential clinical implementations. Semin Immunopathol 33(5):419–440. https://doi.org/10.1007/s00281-010-0233-9
doi: 10.1007/s00281-010-0233-9
pubmed: 21174094
Escudier B, Dorval T, Chaput NJ et al (2005) Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. J Transl Med 3(1):10. https://doi.org/10.1186/1479-5876-3-10
doi: 10.1186/1479-5876-3-10
pubmed: 15740633
pmcid: 554765
Dai S, Wei D, Wu Z et al (2008) Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol Ther 16(4):782–790. https://doi.org/10.1038/mt.2008.1
doi: 10.1038/mt.2008.1
pubmed: 18362931
Morse MA, Garst J, Osada T et al (2005) A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med 3(1):9. https://doi.org/10.1186/1479-5876-3-9
doi: 10.1186/1479-5876-3-9
pubmed: 15723705
pmcid: 551593
Viaud S, Terme M, Flament C et al (2009) Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS One 4(3):e4942. https://doi.org/10.1371/journal.pone.0004942
doi: 10.1371/journal.pone.0004942
pubmed: 19319200
pmcid: 2657211
Munich S, Sobo-Vujanovic A, Buchser WJ et al (2012) Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands. Oncoimmunology 1:1074–1083. https://doi.org/10.4161/onci.20897
doi: 10.4161/onci.20897
pubmed: 23170255
pmcid: 3494621
Sabanovic B, Piva F, Cecati M, Giulietti M (2021) Promising extracellular vesicle-based vaccines against viruses, including SARS-CoV-2. Biology 10(2):94. https://doi.org/10.3390/biology10020094
doi: 10.3390/biology10020094
pubmed: 33513850
pmcid: 7912280
Lattanzi L, Federico M (2012) A strategy of antigen incorporation into exosomes: comparing cross-presentation levels of antigens delivered by engineered exosomes and by lentiviral virus-like particles. Vaccine 30(50):7229–7237. https://doi.org/10.1016/j.vaccine.2012.10.010
doi: 10.1016/j.vaccine.2012.10.010
pubmed: 23099330
Di Bonito P, Ridolfi B, Columba-Cabezas S et al (2015) HPV-E7 delivered by engineered exosomes elicits a protective CD8
doi: 10.3390/v7031079
pubmed: 25760140
pmcid: 4379561
Ferrantelli F, Chiozzini C, Manfredi F et al (2021) Simultaneous CD8
doi: 10.3390/vaccines9030240
Di Bonito P, Chiozzini C, Arenaccio C et al (2017) Antitumor HPV E7-specific CTL activity elicited by in vivo engineered exosomes produced through DNA inoculation. Int J Nanomedicine 12:4579–4591. https://doi.org/10.2147/IJN.S131309
doi: 10.2147/IJN.S131309
pubmed: 28694699
pmcid: 5491702
Anticoli S, Aricò E, Arenaccio C et al (2018) Engineered exosomes emerging from muscle cells break immune tolerance to HER2 in transgenic mice and induce antigen-specific CTLs upon challenge by human dendritic cells. J Mol Med 96(2):211–221. https://doi.org/10.1007/s00109-017-1617-2
doi: 10.1007/s00109-017-1617-2
pubmed: 29282521
Zhao H, Yang L, Baddour J et al (2016) Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism. Elife 5:e10250. https://doi.org/10.7554/eLife.10250
doi: 10.7554/eLife.10250
pubmed: 26920219
pmcid: 4841778
Hoshino A, Costa-Silva B, Shen TL et al (2015) Tumor exosome integrins determine organotropic metastasis. Nature 527(7578):329–335. https://doi.org/10.1038/nature15756
doi: 10.1038/nature15756
pubmed: 26524530
pmcid: 4788391
Arenaccio C, Chiozzini C, Ferrantelli F et al (2019) Exosomes in therapy: engineering, pharmacokinetics and future applications. Curr Drug Targets 20(1):87–95. https://doi.org/10.2174/1389450119666180521100409
doi: 10.2174/1389450119666180521100409
pubmed: 29779478